Private equity firm Osceola Capital has announced the acquisition of two pharmacies, Eagle Pharmacy and Lee Silsby Compounding Pharmacy, by its platform company Revelation Pharma. The acquisitions aim to enhance Revelation’s capabilities and scale in the compounding pharmacy sector. With a total of 18 acquired pharmacies, Revelation has become one of the largest privately-held compounding pharmacy providers in the US. The company offers a diverse range of compounded pharmaceutical solutions across various therapeutic areas and serves thousands of prescribers and patients nationwide.
Osceola Capital announced today the seventeenth and eighteenth additions to the Revelation Pharma (“Revelation” or the “Company”) platform, adding significant scale and capabilities to the business. Revelation acquired Eagle Pharmacy, located in Hoover, Alabama, and Lee Silsby Compounding Pharmacy, located in Beachwood, Ohio. Eagle is a 503B outsourcing compounding pharmacy that serves healthcare facilities, medical offices, patients, and prescribers in over 29 U.S. states & territories, and its capabilities will allow Revelation to ensure availability of medication for office use and provide diversification and additional growth levers for the rest of the Revelation platform. Lee Silsby is a 503A compounding pharmacy that serves patients and prescribers in over 45 U.S. states & territories.
Since its founding in January 2021, Revelation has rapidly scaled both organically and inorganically into one of the largest privately-held compounding pharmacies in the United States. The Company has acquired 18 pharmacies to-date, its organic growth is far outpacing industry growth, and is broadly diversified across every aspect of its business model. Revelation serves tens of thousands of prescribers and hundreds of thousands of patients throughout the U.S. every year. The Company’s geographic footprint includes 14+ locations with licenses and revenue produced in all 50 states. Revelation offers compounded pharmaceutical solutions across a wide variety of therapeutic classes, including allergy, anti-infective, hormone, urology, veterinary, anti-inflammatory, nutrition, men’s health, women’s health, ophthalmology, and more. Revelation’s medication delivery form expertise includes tablet, injection, topical, pellet, and oral.
“Organically, Revelation is expanding significantly above market growth rates through our management team’s adept execution of new pharmacist recruitment initiatives, the development and utilization of new product and service lines, and the expansion de novo locations to maximize capacity availability,” said Patrick Watkins, Partner at Osceola Capital. “The Revelation team, with the support of Osceola Capital, has refined a successful and scalable acquisition playbook to source, execute and integrate targets, and we look forward to further executing on a robust acquisition pipeline.”
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Source: BioSpace